Investors Actively Trade These 4 Healthcare Stocks Post Earnings
Wall St. Cheat Sheet
Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations
Seeking Alpha
Gilead, Bristol Shine at EASL Conference
Motley Fool
Celebrate the Hep C Wins, for Now
Motley Fool
Partner Up or Get Passed Up
Motley Fool
Approval Likely, but Details Still Important
Motley Fool
1 Biotech Punished by Hep-C Overreaction
Motley Fool